ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock Price, Quote, News and Overview
NASDAQ:ARTV - Nasdaq - US04317A1079 - Common Stock - Currency: USD
ARTV Quote, Performance and Key Statistics
2.1
+0.18 (+9.38%)
The current stock price of ARTV is 2.1 USD. In the past month the price increased by 9.38%.
ARTV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.73B | ||
| AMGN | AMGEN INC | 13.29 | 148.31B | ||
| GILD | GILEAD SCIENCES INC | 12.78 | 123.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 60.56B | ||
| ARGX | ARGENX SE - ADR | 327.86 | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 25.03B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.31B | ||
| NTRA | NATERA INC | N/A | 21.77B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.04B | ||
| BIIB | BIOGEN INC | 7.41 | 17.17B |
Related stock screener links
About ARTV
Company Profile
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2024-07-19. The firm is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Company Info
ARTIVA BIOTHERAPEUTICS INC
5505 Morehouse Drive
San Diego CALIFORNIA US
Employees: 89
Phone: 18582674467
ARTIVA BIOTHERAPEUTICS INC / ARTV FAQ
What is the stock price of ARTIVA BIOTHERAPEUTICS INC today?
The current stock price of ARTV is 2.1 USD. The price increased by 9.38% in the last trading session.
What is the ticker symbol for ARTIVA BIOTHERAPEUTICS INC stock?
The exchange symbol of ARTIVA BIOTHERAPEUTICS INC is ARTV and it is listed on the Nasdaq exchange.
On which exchange is ARTV stock listed?
ARTV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARTIVA BIOTHERAPEUTICS INC stock?
12 analysts have analysed ARTV and the average price target is 20.81 USD. This implies a price increase of 890.86% is expected in the next year compared to the current price of 2.1. Check the ARTIVA BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARTIVA BIOTHERAPEUTICS INC worth?
ARTIVA BIOTHERAPEUTICS INC (ARTV) has a market capitalization of 51.16M USD. This makes ARTV a Micro Cap stock.
How many employees does ARTIVA BIOTHERAPEUTICS INC have?
ARTIVA BIOTHERAPEUTICS INC (ARTV) currently has 89 employees.
What are the support and resistance levels for ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?
ARTIVA BIOTHERAPEUTICS INC (ARTV) has a resistance level at 2.49. Check the full technical report for a detailed analysis of ARTV support and resistance levels.
Is ARTIVA BIOTHERAPEUTICS INC (ARTV) expected to grow?
The Revenue of ARTIVA BIOTHERAPEUTICS INC (ARTV) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ARTV EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARTV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARTV, evaluating the profitability, health, valuation and growth aspects
- ARTIVA BIOTHERAPEUTICS INC (ARTV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARTIVA BIOTHERAPEUTICS INC (ARTV) Sales and EPS estimates to see what analysts future expectations are.
- ARTIVA BIOTHERAPEUTICS INC (ARTV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARTIVA BIOTHERAPEUTICS INC (ARTV) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock Chart to make your own analysis
- ARTIVA BIOTHERAPEUTICS INC (ARTV) Latest news and press-releases to stay up to date.
Does ARTIVA BIOTHERAPEUTICS INC (ARTV) stock pay dividends?
ARTV does not pay a dividend.
What is the Price/Earnings (PE) ratio of ARTIVA BIOTHERAPEUTICS INC (ARTV)?
ARTIVA BIOTHERAPEUTICS INC (ARTV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.95).
What is the Short Interest ratio of ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?
The outstanding short interest for ARTIVA BIOTHERAPEUTICS INC (ARTV) is 8.28% of its float. Check the ownership tab for more information on the ARTV short interest.
ARTV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ARTV.
ARTV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARTV. The financial health of ARTV is average, but there are quite some concerns on its profitability.
ARTV Financial Highlights
Over the last trailing twelve months ARTV reported a non-GAAP Earnings per Share(EPS) of -2.95. The EPS decreased by -370.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.19% | ||
| ROE | -35.03% | ||
| Debt/Equity | 0 |
ARTV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to ARTV. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 44.82% and a revenue growth -100% for ARTV